Ashish M. Kamat, MD, MBBS

@UroDocAsh

Endowed Professor, Surgeon | President, International Bladder Cancer Group | Assoc Editor | Views my own

Houston, TX
faculty.mdanderson.org/Ashish_Kamat/D…
Vrijeme pridruživanja: ožujak 2010.
371 fotografija ili videozapis Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @UroDocAsh

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @UroDocAsh

  1. Prikvačeni tweet
    27. srp 2019.

    The entire landscape of on one slide; courtesy Noah Hahn

    "Mapping Progress in Bladder Cancer" This rapidly evolving landscape is incredibly exciting. expands on the progress in bladder cancer & an explosion of clinical trials expanding our options. Full article by on UroToday now.
    40 proslijeđenih tweetova 87 korisnika označava da im se sviđa
    Poništi
  2. prije 21 sat

    Amen! The seeds of are being planted much too early

    Having ended up in medicine myself very unexpectedly, this piece by Dr. speaks to me. We’ve opted out of the ‘arms race’ w/ our 3 kids. Our goal is to raise kind, grateful humans who leave the world in some way better than they found it.
    5 korisnika označava da im se sviđa
    Poništi
  3. 1. velj

    It’s great to hear about when jibes like these drive people to achieve more; Unfortunately the truth is these comments likely deflate a larger number of talented folks into self doubt and dejection

    This reminds me of when I told my Harvard med professor I was applying to MGH for residency and he said I couldn't get in because MGH is for stars. I am a star he just couldn't see it
    7 korisnika označava da im se sviđa
    Poništi
  4. 31. sij

    What are these papers that you speak of?

    2 proslijeđena tweeta 26 korisnika označava da im se sviđa
    Poništi
  5. 30. sij

    Are Molecular Markers for Ready for Prime Time? Nathan Brooks

    17 proslijeđenih tweetova 31 korisnik označava da mu se sviđa
    Poništi
  6. 28. sij

    One of the greatest joys of being in academia is the opportunity to be part of my mentees journey

    Thank a mentor week 👍 Richie, D’Amico, DeWolf, from the Brigham days 🙏 many, many others
    Prikaži ovu nit
    11 korisnika označava da im se sviđa
    Poništi
  7. proslijedio/la je Tweet
    27. sij

    Advancements in treating : Pembrolizumab FDA-approved for high risk non-muscle invasive . on UroToday >

    2 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Poništi
  8. 28. sij

    Yes. This.

    Today’s decision by to cover FDA-approved or cleared NGS tests for patients with germline ovarian or breast cancer is an important step to ensuring access to tests that target the right treatments to the right patients at the right time.
    Prikaži ovu nit
    3 korisnika označavaju da im se sviđa
    Poništi
  9. 27. sij

    Not too surprised that IMvigor010 did not meet primary endpoint of DFS for IO (atezolizumab) as adjuvant after cystectomy, versus observation in high risk MIBC

    Clinically bad, scientifically intriguing news. Is IO similar to chemo in ? (Neoadj >> Adj)
    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
    Poništi
  10. 23. sij

    The key to immortality is to first live a life worth remembering

    1 reply 1 proslijeđeni tweet 14 korisnika označava da im se sviđa
    Poništi
  11. 22. sij

    Supports my bias that experienced urologists are ~95% accurate in predicting which tumors are NMIBC; less so in identifying which are not What’s your experience:

    We’ve used a Likert scale at initial flexible cystoscopy (see image) to triage. Likert 1-2 are around 95% NMIBC at TURBT in , Likert 3-5 around 50% MIBC in control arm of the trial
    1 reply 8 korisnika označava da im se sviđa
    Poništi
  12. 22. sij

    Risk Adapted Management of Low‐Grade Bladder Tumors: Recommendations from the IBCG (International Bladder Cancer Group)

    , , i još njih 7
    24 proslijeđena tweeta 69 korisnika označava da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    21. sij

    What do your radical cystectomy patients know about ? Share the SIU-ERAS Patient Information Brochure available on with your patients and keep them updated.

    6 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  14. 21. sij

    Excellent work on costs of RC versus TMT in by But: we still need to encourage patients who cannot - or do not want to - undergo RC to receive TMT as a very viable option Too many patients not receiving any curative therapy at all !

    The cost of muscle-invasive bladder cancer treatments, hosts on discussing "Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients with Localized MIBC." on UroToday.
    6 proslijeđenih tweetova 16 korisnika označava da im se sviđa
    Poništi
  15. 21. sij

    ᴛʜᴇ ғᴏᴏʟ ᴅɪᴅɴ'ᴛ ᴋɴᴏᴡ ɪᴛ ᴡᴀs ɪᴍᴘᴏssɪʙʟᴇ. sᴏ ʜᴇ ᴅɪᴅ ɪᴛ.

    4 proslijeđena tweeta 16 korisnika označava da im se sviđa
    Poništi
  16. proslijedio/la je Tweet
    19. sij

    Are Molecular Markers for Bladder Cancer Ready for Prime Time?

    16 proslijeđenih tweetova 26 korisnika označava da im se sviđa
    Poništi
  17. 17. sij

    . The US needs access to other stations of BCG so we can catch up with EU!

    landscape of strain availability in Europe, data from Jacques Irani
    1 proslijeđeni tweet 12 korisnika označava da im se sviđa
    Poništi
  18. 17. sij

    This. Yes!

    Over time I have stopped using the four words “Clinical correlation is recommended” in my reports. In fact I delete it if the report was dictated by the fellow. The late Jack Yardley said clinicians are supposed to correlate, that’s their job. What do other do?
    5 korisnika označava da im se sviđa
    Poništi
  19. 17. sij

    Useful tool to counsel patients considering options Kudos to Karen Hoffman et al

    6 korisnika označava da im se sviđa
    Poništi
  20. 15. sij

    Rules to live by - the concept of

    8 proslijeđenih tweetova 23 korisnika označavaju da im se sviđa
    Poništi
  21. 14. sij

    This has been the practice in many countries where BCG is not specifically formulated for Hope this work by et al will help adoption of practice in US

    Bacillus Calmette-Guerin () Packaged for Percutaneous Vaccination Can Be Used for Intravesical Instillation | Strong work ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩
    2 proslijeđena tweeta 15 korisnika označava da im se sviđa
    Poništi

@UroDocAsh još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·